Skip to main content

Table 2 Between-arm differences in overall survival over time

From: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

  PFS interim (7-month follow-up) PFS update (12-month follow-up) PFS final (18-month follow-up)
Cutoff date Feb 11, 2011 Jul 8, 2011 Dec 15, 2011
OS events, n
 EVE vs PBO, % of events
83
10.6 vs 13.0
137
17.3 vs 22.7
200
25.4 vs 32.2
Δ OS events, % of events 2.4 5.4 6.8
  1. EVE everolimus, OS overall survival, PBO placebo, PFS progression-free survival, Δ change